Ignite Creation Date:
2024-10-25 @ 7:56 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06634160
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-04
Brief Title:
Assessment of the Prevalence of Steatotic Liver Disease Associated with Metabolic Dysfunction in Patients with Heterozygous Familial Hypercholesterolemia
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease MASLD Prevalence in Patients with Heterozygous Familial Hypercholesterolemia HeFH the STEATO-FH Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STEATO-FH
Brief Summary:
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population
Detailed Description:
Investigators will include patients being followed for heterozygous familial hypercholesterolemia in their centers The prevalence of hepatic steatosis will be studied non-invasively using Fibroscan In addition coronary calcium score CAC scores will be evaluated and a biocollection will be performed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None